Company Gets a $3 Million Phase IIB SBIR Grant to Advance GTC-3295 to IND-Enabling Preclinical Studies LEXINGTON, KY. and NEW YORK, NY. (August 25, 2023) – Gismo Therapeutics Inc. has been awarded a phase IIB SBIR grant to continue development of therapies to treat Alzheimer’s Disease. A $1.19 Million SBIR grant award represents the third [...]
Company Gets Grants from the Michael J. Fox Foundation for Parkinson’s Research and from the Department of Defense. LEXINGTON, KY. and NEW YORK, NY. (June 16, 2022) – Gismo Therapeutics Inc. has been awarded two new grants to continue development of therapies to treat Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS). A $280,000 grant entitled [...]
Company Gets Two Grants to Advance its Drug Discovery Pipeline LEXINGTON, KY. and NEW YORK, NY. (June 14, 2019) – Gismo Therapeutics Inc. has been awarded two grants to continue its development of therapies to treat Alzheimer’s Disease. A $952,480 SBIR grant award represents a second year of a $1.88 million grant, entitled "Glycosaminoglycan-Interacting Small [...]
Biotech Startup Receives More Funds to Advance its Drug Discovery Program LEXINGTON, Ky. and QUEENS, N.Y. (Oct. 12, 2017) – Gismo Therapeutics Inc. has been awarded two grants to continue its development of therapies to treat Parkinson’s Disease. A $384,000 SBIR grant entitled "Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic" was awarded by the National [...]
Biotech Startup, Collaborator Receive Parkinson's Disease Grant to Study Newly Identified Pathway, Develop Novel Treatments Lexington, Kentucky (PRWEB) December 03, 2014 Gismo Therapeutics Inc. is pleased to announce that it has been awarded a $235,000 Michael J. Fox Foundation for Parkinson's Research grant to investigate therapeutics directed against a newly identified disease pathway in Parkinson’s disease. [...]
Biotech Company Receives SBIR Grant, Identifies Lead Compounds and Files Patent Application Lexington,Kentucky and Queens, New York (PRWEB) October 02, 2014 Gismo Therapeutics Inc. is pleased to announce funding received to investigate therapeutics directed against a newly identified disease pathway in Alzheimer’s disease. A grant award from the Small Business Innovation Research (SBIR) Program, National Institute [...]